Trulicity - supply shortage
Ongoing
dulaglutide
ShortageHuman
Shortage information
Trulicity is a medicine used in addition to diet and exercise in adults and children from 10 years of age who have type 2 diabetes.
It is used:
- on its own when use of metformin (another medicine for type 2 diabetes) is not recommended;
- as an ‘add-on’ to other diabetes medicines.
There has been an increase in demand for Trulicity, which has led to intermittent supply shortages. These are expected to continue at least until the end of 2024 in most affected EU Member States. The supply shortage is not related to a quality defect of the product or a safety issue.
Austria, Belgium, Finland, Hungary, Italy, Netherlands, Portugal, Spain and Sweden are currently affected or are at risk of being affected by the shortage.
This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, contact the national competent authority.
EMA’s SPOC working party is closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to identify measures to mitigate the impact of the supply shortage.
The SPOC working party is responsible for monitoring and reporting events that could affect the supply of medicines in the EU.
- An increase in demand for Trulicity has led to intermittent supply shortages that are expected to continue at least until the end of 2024 in most affected EU Member States.
- Healthcare professionals should ensure that patients at risk of running out of Trulicity are switched in time to a suitable alternative.
- For additional information, consult your country’s national shortage register or national competent authority.
- An increase in demand for Trulicity has led to intermittent supply shortages that are expected to continue at least until the end of 2024 in most affected EU Member States.
- If you are at risk of running out of Trulicity, your doctor will discuss with you the need to switch to a suitable alternative.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s national shortage register or national competent authority.
Key facts
- Medicines affected
- Trulicity
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- dulaglutide
- Therapeutic area (MESH)
- Diabetes Mellitus, Type 2
- Pharmaceutical forms affected
- Solution for injection in pre-filled pen
- Strengths affected
- 0.75 mg
- 1.5 mg
- 3 mg
- 4.5 mg
- Availability of alternatives
- Yes
Key dates
- First published
- Last updated